Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10035352 | 0.97 | OXTR (0.51) | OXTRGLAMEN1KMT2AMAPK1 | |
| SCHEMBL10035343 | 0.97 | OXTR (0.51) | OXTRGLAMEN1KMT2AMAPK1 | |
| SCHEMBL10035329 | 0.86 | HPGD (0.51) | OXTRGLAMEN1KMT2AMAPK1 | |
| SCHEMBL10035357 | 0.85 | OXTR (0.64) | OXTRGLAMEN1KMT2AMAPK1 | |
| SCHEMBL17223083 | 0.85 | CYP2A6 (0.54) | OXTRHPGDSMN1; SMN2ALDH1A1CYP19A1 | |
| SCHEMBL10035350 | 0.83 | OXTR (0.69) | OXTRGLAMEN1KMT2AMAPK1 | |
| SCHEMBL10035326 | 0.83 | OXTR (0.69) | OXTRGLAMEN1KMT2AMAPK1 | |
| SCHEMBL10035332 | 0.83 | UCHL3 (0.47) | OXTRGLAMEN1KMT2AMAPK1 | |
| SCHEMBL10035331 | 0.82 | KDM4E (0.55) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP19A1 | |
| SCHEMBL10035355 | 0.82 | SMN1; SMN2 (0.55) | OXTRGLAMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101771-B2 | Triazole derivative, and light-emitting element, light-emitting device, and electronic device using triazole derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8101771-B2 | Triazole derivative, and light-emitting element, light-emitting device, and electronic device using triazole derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20100079066-A1 | Triazole Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Triazole Derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20100079066-A1 | Triazole Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Triazole Derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100079066-A1 | Triazole Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Triazole Derivative | TTI1, TTI2, NLRP3 | OXTR 3599/4885GLA 2899/4885MEN1 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.